Try our Advanced Search for more refined results

Seagen Inc. v. Daiichi Sankyo Co., Ltd.

  1. January 17, 2024

    PTAB Nixes Seagen Cancer Drug IP After Daiichi Verdict

    The Patent Trial and Appeal Board has said Daiichi Sankyo was able to show that the challenged claims of a Seagen cancer drug patent, which a Texas federal jury found Daiichi infringed in a $42 million verdict in 2022, were invalid.

  2. February 15, 2023

    In 3rd Reversal, PTAB Will Eye Seagen Patent In $42M Case

    Reversing itself for the third time, the Patent Trial and Appeal Board has agreed to review a Seagen cancer drug patent, finding that Daiichi Sankyo, which a Texas jury told to pay $42 million for infringing the patent, presented "compelling evidence" that it is invalid.

  3. August 12, 2022

    Seagen Eyes $12M In Atty Fees On Top Of $42M Daiichi Verdict

    Morrison Foerster-led Seagen has urged U.S. District Judge Rodney Gilstrap to award it up to $12 million in attorney fees after a jury determined rival Daiichi Sankyo owed it $41.8 million for infringing a patent on breast cancer drug Adcetris, arguing that its competitor deliberately obstructed discovery.

  4. July 18, 2022

    Seagen Gets PGR Nixed Under Fintiv In Rehearing Decision

    Seagen Inc. has persuaded the Patent Trial and Appeal Board on rehearing to deny a challenge from Daiichi Sankyo Inc. and AstraZeneca Pharmaceuticals LP to its cancer antibody patent, with the board saying the post-grant review is no longer warranted under the controversial Fintiv precedent.

  5. July 18, 2022

    Gilstrap Says AstraZeneca Rival Had No Undue Delay In IP Suit

    U.S. District Judge ​​Rodney Gilstrap has made another ruling on the issue of whether a patent was prosecuted poorly enough to merit undoing an infringement verdict, in this instance rejecting AstraZeneca and Daiichi Sankyo's argument that a 15-year delay should sink a nearly $42 million jury loss over AstraZeneca's bestselling breast cancer drug Enhertu.

  6. May 16, 2022

    Gilstrap Won't Pause $42M Seagen Drug Patent Row For PTAB

    U.S. District Judge Rodney Gilstrap has refused to halt post-trial proceedings following a $42 million patent infringement verdict against Daiichi Sankyo, denying its request to wait for the Patent Trial and Appeal Board to review Seagen's patent for cancer drug Adcetris.

  7. April 08, 2022

    PTAB To Review Cancer Antibody IP That Drew $41.8M Verdict

    The Patent Trial and Appeal Board has agreed to review a Seagen Inc. antibody patent after the board previously used its discretion to reject two challenges from Daiichi Sankyo Inc. and AstraZeneca while a Texas federal jury on Friday found Daiichi willfully infringed the patent to the tune of $41.8 million.

  8. April 08, 2022

    Daiichi Hit With $41.8M Verdict In Cancer Drug IP Fight

    A Texas federal jury found on Friday that Daiichi Sankyo Co. Ltd. owes $41.8 million in damages because a breast cancer treatment medication it markets under the brand name Enhertu infringes a Seagen Inc. patent covering the delivery of a drug called Adcetris.

  9. March 16, 2022

    Daiichi Sankyo Hit With $75K Legal Bill Before Patent Trial

    U.S. District Judge Rodney Gilstrap has rejected a legal effort by Daiichi Sankyo and AstraZeneca to get out of a patent lawsuit over a breast cancer treatment drug they both sell and also ordered Daiichi to pay $75,000 in legal fees for what a rival called "discovery malfeasance."

  10. June 30, 2021

    Gilstrap Says Patent Suit Was Filed Right On Time

    U.S. District Judge Rodney Gilstrap has ruled that the one-hour time difference between his Texas court and the U.S. Patent and Trademark Office in Virginia is not enough to sink an infringement suit lodged against a new Daiichi Sankyo breast cancer drug — filed two minutes after the asserted patent was issued.

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!